Skip to content

Retrospective Cohort Study on the Effects of Secukinumab versus Acitretin Capsules in Preventing the Progression of Moderate-to-Severe Plaque Psoriasis to Psoriatic Arthritis

Retrospective Cohort Study on the Effects of Secukinumab versus Acitretin Capsules in Preventing the Progression of Moderate-to-Severe Plaque Psoriasis to Psoriatic Arthritis

Status
Active, not recruiting
Phases
Phase 4
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500109183
Enrollment
Unknown
Registered
2025-09-15
Start date
2025-09-15
Completion date
Unknown
Last updated
2025-09-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Psoriasis and psoriatic arthritis

Interventions

Observation group:NA

Sponsors

The First Affiliated Hospital of Army Medical University PLA
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1.Aged 18-65 years, with sequential diagnoses of plaque psoriasis (or psoriasis vulgaris) and psoriatic arthritis (or arthropathic psoriasis) (PsO + PsA); 2.With complete 1-year follow-up imaging data (MRI/ultrasound + X-ray); 3.Baseline imaging (MRI/ultrasound) shows subclinical joint lesions (such as bone marrow edema, synovial thickening); 4.Treated with secukinumab for >=12 months, or acitretin for >=12 months.

Exclusion criteria

Exclusion criteria: 1.Complicated with rheumatoid arthritis, ankylosing spondylitis, other autoimmune diseases, and malignant tumors; 2.There is radiological bone erosion at baseline (mSvdH score >= 5); 3.Follow-up time less than 1 year; 4.The quality of the examination images is poor, making accurate assessment impossible.

Design outcomes

Primary

MeasureTime frame
Imaging score;

Secondary

MeasureTime frame
Psoriasis Area and Severity Index;Joint improvement status;

Countries

China

Contacts

Public ContactYin Rui

The First Affiliated Hospital of Army Medical University PLA

swyinrui@163.com+86 23 68766333

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026